英克勒庫單抗

英克勒庫單抗
單株抗體
種類	完整抗體
目標	P選擇素（英語：P-selectin）
臨床資料
其他名稱	LC1004-002
ATC碼	未分配;
識別資訊
CAS號	1256258-86-2
ChemSpider	none;
UNII	A6734I702L;
KEGG	D10356;
化學資訊
化學式	C6452H9930N1730O2024S42
摩爾質量	145,465.02 g·mol−1

英克勒庫單抗（INN：Inclacumab；開發代號：LC1004-002）是一種人單株抗體，設計用於治療心血管疾病，如心肌梗塞。^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]該藥物已獲得羅氏公司許可。^[10]

參考資料

^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106 (PDF). WHO Drug Information. 2011, 25 (4) [2024-01-21]. （原始內容存檔 (PDF)於2016-03-04）.
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Inclacumab （頁面存檔備份，存於互聯網檔案館）, American Medical Association.
^ Stähli BE, Gebhard C, Duchatelle V, Cournoyer D, Petroni T, Tanguay JF, Robb S, Mann J, Guertin MC, Wright RS, L L'Allier P, Tardif JC. Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT-ACS Trial. J Am Heart Assoc. November 2016, 5 (11). PMC 5210344 . PMID 27852589. doi:10.1161/JAHA.116.004255.
^ Stähli BE, Tardif JC, Carrier M, Gallo R, Emery RW, Robb S, Cournoyer D, Blondeau L, Johnson D, Mann J, Lespérance J, Guertin MC, L'Allier PL. Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery: SELECT-CABG Trial. J. Am. Coll. Cardiol. January 2016, 67 (3): 344–6. PMID 26796402. doi:10.1016/j.jacc.2015.10.071 .
^ Morrison M, Palermo G, Schmitt C. Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of inclacumab in healthy Japanese and Caucasian subjects. Eur. J. Clin. Pharmacol. November 2015, 71 (11): 1365–74. PMID 26363899. S2CID 468125. doi:10.1007/s00228-015-1938-4.
^ Schmitt C, Abt M, Ciorciaro C, Kling D, Jamois C, Schick E, Solier C, Benghozi R, Gaudreault J. First-in-Man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin. J. Cardiovasc. Pharmacol. June 2015, 65 (6): 611–9. PMC 4461388 . PMID 25714598. doi:10.1097/FJC.0000000000000233.
^ Schmitt C, Mudie N, Ciorciaro C, Gaudreault J. Absence of pharmacodynamic interaction between inclacumab and heparin in healthy smokers. J. Cardiovasc. Pharmacol. April 2015, 65 (4): 386–92. PMID 25602360. S2CID 19526048. doi:10.1097/FJC.0000000000000211.
^ Tardif JC, Tanguay JF, Wright SR, Duchatelle V, Petroni T, Grégoire JC, Ibrahim R, Heinonen TM, Robb S, Bertrand OF, Cournoyer D, Johnson D, Mann J, Guertin MC, L'Allier PL. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J. Am. Coll. Cardiol. May 2013, 61 (20): 2048–55. PMID 23500230. doi:10.1016/j.jacc.2013.03.003 .
^ Kling D, Stucki C, Kronenberg S, Tuerck D, Rhéaume E, Tardif JC, Gaudreault J, Schmitt C. Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab--preclinical and clinical studies. Thromb. Res. May 2013, 131 (5): 401–10. PMID 23522853. doi:10.1016/j.thromres.2013.02.020.
^ Form 8K - Entry into a Material Definitive Agreement Between Global Blood Therapeutics, Inc. and Hoffmann-La Roche Inc.. United States Securities and Exchange Commission.

[1] World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106 (PDF). WHO Drug Information. 2011, 25 (4) [2024-01-21]. （原始內容存檔 (PDF)於2016-03-04）.

[2] Statement On A Nonproprietary Name Adopted By The USAN Council - Inclacumab （頁面存檔備份，存於互聯網檔案館）, American Medical Association.

[3] Stähli BE, Gebhard C, Duchatelle V, Cournoyer D, Petroni T, Tanguay JF, Robb S, Mann J, Guertin MC, Wright RS, L L'Allier P, Tardif JC. Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT-ACS Trial. J Am Heart Assoc. November 2016, 5 (11). PMC 5210344 . PMID 27852589. doi:10.1161/JAHA.116.004255.

[4] Stähli BE, Tardif JC, Carrier M, Gallo R, Emery RW, Robb S, Cournoyer D, Blondeau L, Johnson D, Mann J, Lespérance J, Guertin MC, L'Allier PL. Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery: SELECT-CABG Trial. J. Am. Coll. Cardiol. January 2016, 67 (3): 344–6. PMID 26796402. doi:10.1016/j.jacc.2015.10.071 .

[5] Morrison M, Palermo G, Schmitt C. Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of inclacumab in healthy Japanese and Caucasian subjects. Eur. J. Clin. Pharmacol. November 2015, 71 (11): 1365–74. PMID 26363899. S2CID 468125. doi:10.1007/s00228-015-1938-4.

[6] Schmitt C, Abt M, Ciorciaro C, Kling D, Jamois C, Schick E, Solier C, Benghozi R, Gaudreault J. First-in-Man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin. J. Cardiovasc. Pharmacol. June 2015, 65 (6): 611–9. PMC 4461388 . PMID 25714598. doi:10.1097/FJC.0000000000000233.

[7] Schmitt C, Mudie N, Ciorciaro C, Gaudreault J. Absence of pharmacodynamic interaction between inclacumab and heparin in healthy smokers. J. Cardiovasc. Pharmacol. April 2015, 65 (4): 386–92. PMID 25602360. S2CID 19526048. doi:10.1097/FJC.0000000000000211.

[8] Tardif JC, Tanguay JF, Wright SR, Duchatelle V, Petroni T, Grégoire JC, Ibrahim R, Heinonen TM, Robb S, Bertrand OF, Cournoyer D, Johnson D, Mann J, Guertin MC, L'Allier PL. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J. Am. Coll. Cardiol. May 2013, 61 (20): 2048–55. PMID 23500230. doi:10.1016/j.jacc.2013.03.003 .

[9] Kling D, Stucki C, Kronenberg S, Tuerck D, Rhéaume E, Tardif JC, Gaudreault J, Schmitt C. Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab--preclinical and clinical studies. Thromb. Res. May 2013, 131 (5): 401–10. PMID 23522853. doi:10.1016/j.thromres.2013.02.020.

[10] Form 8K - Entry into a Material Definitive Agreement Between Global Blood Therapeutics, Inc. and Hoffmann-La Roche Inc.. United States Securities and Exchange Commission.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]